摘要
目的:比较XELOX方案及mFOL-FOX6方案在Ⅲ期胃癌患者术后辅助化疗中应用的耐受性,及两组患者3年生存率的差异。方法:分析2004-01-2007-0460例接受术后辅助化疗的Ⅲ期胃癌患者,其中31例患者接受XELOX方案化疗,29例患者接受mFOLFOX6方案化疗,根据NCI-CTC3.0毒性标准来评价化疗的毒性,Kap-lan-Meier法比较两组患者的3年生存率。结果:XELOX组手足综合征发生率明显高于FOLFOX组(51.6%vs13.8%,P<0.05)。两组患者Ⅲ～Ⅳ度毒性发生率均较低,最常见的是恶心呕吐(32.2%vs34.5%)和白细胞下降(12.8%vs17.2%),无治疗相关的死亡。XELOX组和FOLFOX组的3年生存率分别为48.3%和63.0%,差异无统计学意义,P=0.122。XELOX组平均生存期为31.3个月,FOLFOX组为37.4个月,P=0.204。结论:Ⅲ期胃癌患者术后接受XE-LOX方案和FOLFOX方案辅助化疗毒性低、耐受性好、疗效相当,均优于5-FU单药辅助化疗,5-FU联合奥沙利铂的方案将成为胃癌辅助化疗首选方案。
OBJECTIVE：Comparing tolerance and 3-year survival rate of XELOX regimen and mFOLFOX6 regimen applying in adjuvant chemotherapy in patients with stage Ⅲ gastric cancer.METHODS：Retrospective analyzed consecutive 60 gastric cancer patients with stage Ⅲ gastric cancer from January 2004 to April 2007,among them 31 patients received XELOX regimen,29 received FOLFOX regimen post operatively.NCI-CTC 3.0 criteria was used to evaluate the toxicity.Three year survival rate was compared with Kaplan-Meier survival curves.RESULTS：The adverse events occurrence rate in the two group were not significant different,except the occurrence of hand-foot syndrome was significantly higher in the XELOX group（51.6% vs 13.8%,P0.05）.The most common grade Ⅲ-Ⅳ adverse events in both groups were nausea/vomiting （32.2% vs 34.5%） and white blood cell decrease（12.8% vs 17.2%）.The 3-year survival rate in XELOX and FOLFOX group was 48.3% and 63.0% respectively （P=0.122）.The estimate mean survival time were 31.3 months and 37.4 months respectively （P=0.204）.CONCLUSIONS：Both XELOX regimen and mFOLFOX6 regimen are safe and well tolerated when applying in patients with stage Ⅲ gastric cancer.The efficacy of the two regimens is identical.Regimens containing both 5-fluorouracil and oxaliplatin are superior to 5-fluorouracil alone and should be first choice regimens in adjuvant setting treating stage Ⅲ gastric cancer patients.
出处
《中华肿瘤防治杂志》
CAS
2010年第18期1470-1472,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
广东省自然科学基金博士启动项目(94510089010-02630)
关键词
胃肿瘤
辅助化疗
5-氟尿嘧啶
奥沙利铂
药物疗法
联合
gastric neoplasms
adjuvant chemotherapy
5-fluorouracil
oxaliplatin
drug therapy
combination
